AXA1125

|date=AXA1125 or LIVRQNac is a new drug developed by Axcella Therapeutics which is currently in clinical trials for post-exertional fatigue caused by Long COVID. AXA1125 has been described as a "novel composition of amino acids" and a "metabolic modulator" and consists of five amino acids (arginine, glutamine, isoleucine, leucine, and valine) and N-acetylcysteine (NAC). |date= |date===Theory== |date=AXA1125 is a endogenous metabolic modulator, which means it consists of naturally occurring substances that act in a way that modulates energy metabolism. AXA1125 was designed to treat non-alcoholic liver conditions. |date= |date====Amino acids and precusors=== |date=AXA1125 consists of a combination of: |date=*Arginine |date=*Glutamine |date=*Isoleucine |date=*Leucine |date=*Valine |date=*N-acetylcysteine (NAC), a precursor to several amino acids |date= |date===Evidence== |date= |date===Clinicians== |date= |date===Risks and safety== |date= |date===Costs and availability== |date= |date===See also == |date=*Post-exertional malaise |date=*Long COVID |date=*Fatigue |date= |date===Learn more == |date=*Oxford test potential treatment for fatigue in long COVID patients - Oxford University |date=*Poster: Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers - Axcella Health Inc. |date= |date===References == |date= |date= |date= |date= |date= |date= |date=